Why Pfizer Stock Is Sinking Today
Pfizer announced that it won't advance a twice-daily version of weight-loss pill danuglipron into phase 3 testing. The decision was made due to high rates of side effects and discontinuations in a ...
Pfizer Scraps Obesity Pill Study, Stock Hits 3-Year Lows
Pfizer Inc (NYSE:PFE) has been trying to nudge its way into the weight-loss drug buzz with its own twice-daily version called danuglipron.
Pfizer shares knocked by fat drug trial setback
Shares in Pfizer Inc (NYSE:PFE) dropped 6% after its highly touted weight loss pill danuglipron showed significant side effects, stopping people from using it. Pfizer will now focus on a once-daily...
Pfizer Pulls Experimental Twice-Daily Weight Loss Drug—Shares Slide 6% To Multiyear Low
Investors' have lost their appetite for Pfizer (shares down about 40% this year) and turned their heads toward injectable weight loss drug makers Eli Lilly (shares up 60%) and Novo Nordisk (shares ...
Pfizer Stops Developing Weight-Loss Pill
Pfizer stops developing its experimental weight-loss pill. More than half of patients in the study had to stop taking danuglipron due to nausea and vomiting, according to a statement Friday.
Pfizer's Weight Loss Drug Won't Enter a Phase 3 Trial. The Stock Drops.
'We believe an improved once-daily formulation of danuglipron could play an important role in the obesity treatment paradigm,' Pfizer said.
Pfizer's stock falls 4% after saying it will not move to Phase 3 trial of weight-loss drug as twice-daily formation
Pfizer Inc.'s stock PFE, +1.30% fell 4% premarket Friday, after the company said it's not planning to push ahead to a Phase 3 trial of a twice-daily formulation of its oral GLP-1 candidate in adult...
Pfizer drops plan to study twice-daily obesity pill in late-stage studies
Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients in a mid-stage trial dropped out with high rates of...
Pfizer to discontinue twice-daily weight loss pill due to high rates of adverse side effects
Pfizer said it still plans to release phase two trial data on a once-a-day version of its weight loss drug, known as danuglipron, in mid-2024.
Texas AG Sues Pfizer Over Covid Vaccine Effectiveness
Attorney General Ken Paxton alleges Pfizer also attempted to silence critics of its vaccine.
Pfizer is sued by Texas over COVID-19 vaccine claims
Pfizer has been sued by Texas Attorney General Ken Paxton, who on Thursday accused the drugmaker of misrepresenting the efficacy of its widely-used COVID-19 vaccine.
Why Is Pfizer (PFE) Down 1.4% Since Last Earnings Report?
Pfizer (PFE) reported earnings 30 days ago. What's next for the stock?
Pfizer Inc. (PFE) 6th Annual Evercore ISI HealthCONx Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) 6th Annual Evercore ISI HealthCONx Conference November 28, 2023 10:50 AM ET Company Participants Dave Denton - CFO and EVP Conference Call Participants Umer Raffat - Evercor...
ChatGPT predicts Pfizer stock price for start of 2024
While Pfizer (NYSE: PFE) surged and became a household name during the COVID-19 pandemic due to the demand for its vaccines, the company has been on a decisive downward trajectory ever since.
Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips
It's always and forever a market of stocks, not a stock market. The Nasdaq is up 45% YTD, while Pfizer Inc. stock is down 40%. Pfizer's yield is at 14-year highs, nearly 30% undervalued. The collap...
Related Companies